Fig. 3: Clinical outcomes by liver involvement in response-evaluable patients with MSS mCRC (n = 101). | Nature Medicine

Fig. 3: Clinical outcomes by liver involvement in response-evaluable patients with MSS mCRC (n = 101).

From: Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial

Fig. 3

Liver involvement was characterized as patients with active LM, treated LM that were resected or ablated without recurrence or no history of LM. No active LM included patients with treated LM together with patients with no history of LM. a, PFS. b, OS.

Back to article page